Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Racial, Ethnic and Socioeconomic Diversity and Outcomes of Patients with Graft-versus-Host Disease: A CIBMTR Analysis.
Farhadfar N, Rashid N, Chen K, DeVos JD, Wang T, Ballen KK, Beitinjaneh A, Bhatt VR, Hamilton BK, Hematti P, Gadalla SM, Solomon SR, El Jurdi N, Lee CJ, MacMillan ML, Rangarajan HG, Schoemans HM, Sharma A, Spellman SR, Wingard JR, Lee SJ. Farhadfar N, et al. Among authors: solomon sr. Blood Adv. 2024 May 22:bloodadvances.2024013074. doi: 10.1182/bloodadvances.2024013074. Online ahead of print. Blood Adv. 2024. PMID: 38776400
Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.
Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Rodriguez-Otero P, et al. Among authors: solomon sr. Future Oncol. 2024 Apr 23. doi: 10.2217/fon-2023-0954. Online ahead of print. Future Oncol. 2024. PMID: 38651976 Review.
Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M. Abramson JS, et al. Among authors: solomon sr. Future Oncol. 2024 Mar 28. doi: 10.2217/fon-2023-0898. Online ahead of print. Future Oncol. 2024. PMID: 38547003 Review.
Navigating Uncertainty in Clinical Practice: A Structured Approach.
Patel B, Gheihman G, Katz JT, Begin AS, Solomon SR. Patel B, et al. Among authors: solomon sr. J Gen Intern Med. 2024 Apr;39(5):829-836. doi: 10.1007/s11606-023-08596-4. Epub 2024 Jan 29. J Gen Intern Med. 2024. PMID: 38286969 Review.
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.
Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV, Abramson JS, Arnason J, Ghosh N, Mehta A, Andreadis C, Solomon SR, Kostic A, Dehner C, Espinola R, Peng L, Ogasawara K, Chattin A, Eliason L, Palomba ML. Wang M, et al. Among authors: solomon sr. J Clin Oncol. 2024 Apr 1;42(10):1146-1157. doi: 10.1200/JCO.23.02214. Epub 2023 Dec 10. J Clin Oncol. 2024. PMID: 38072625 Clinical Trial.
101 results